Sociedad Americana de Hirudoterapia

Effect of vasopressor use on digit survival after replantation and revascularization - a large retrospective cohort study

Retrospective study published in Microsurgery (2019)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosRetrouvey H et al. · Microsurgery, 2019

Abstract

PURPOSE: Despite the common use of intraoperative vasopressors in hand microsurgery, the association between intraoperative vasopressor use and digital replant failure has not yet been examined. Our study aims to examine the association between intraoperative vasopressor use (phenylephrine and/or ephedrine) and postoperative digital failure of replanted or revascularized digits. METHODS: All patients from a single tertiary hand center who underwent unilateral digital replantation or revascularization procedures between 2005 and 2016 were included in this retrospective cohort study. The relationship between intraoperative vasopressors used to maintain hemodynamic stability and digit failure was then evaluated using logistic regression. Specifically, phenylephrine (total dose 10-3,600 mcg) and ephedrine (5-110 mg) use were evaluated. RESULTS: During the study period, 281 patients underwent digital replantation or revascularization. Of those, 86 (31%) were given an intraoperative vasopressor. Digit failure was more likely in patients with crush or avulsion injuries compared to clean-cut mechanism (odds ratio [OR] 2.02, p = .02), and in patients with replantation (OR 7.85, p < .0001) as compared to revascularization procedures. Using multivariate logistic regression adjusting for age, sex, smoking status, comorbidities, number of digits injured, injury type, and procedure type, the odds of digital failure with vasopressor use were not increased (p = .84). When evaluating vasopressors used after tourniquet deflation, failure increased with ephedrine use (OR = 2.42, p = .0496) and phenylephrine use (OR = 2.21, p = .31). CONCLUSIONS: The use of vasopressors was not associated with failure if administration of vasopressors was before tourniquet deflation. The administration of vasopressors after tourniquet deflation should be cautioned.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAdultAmputation, TraumaticEphedrineFemaleFinger InjuriesHumansIntraoperative CareLogistic ModelsMaleMicrosurgeryMiddle AgedPhenylephrine

Resumen

Cohort of 281 digital replant/revascularization patients showing vasopressor use after tourniquet deflation increased failure odds (ephedrine OR 2.42, phenylephrine OR 2.21). Pre-tourniquet-deflation use safe.

Por qué esto importa para la hirudoterapia

This large retrospective cohort study (281 patients) examined whether intraoperative vasopressor use (phenylephrine and/or ephedrine) during digital replantation or revascularization was associated with digit failure. Multivariate analysis found no increased failure risk when vasopressors were given before tourniquet deflation, but ephedrine use after deflation was associated with higher failure (OR 2.42, p=0.0496). The relevance to ASH's domain is indirect: this study concerns perioperative pharmacologic management in the same microsurgical replantation setting where medicinal leeches may be used for venous congestion, but it does not mention leeches or leech therapy. No direct evidence about hirudotherapy is provided, and the study is retrospective and single-center.

Citación

Effect of vasopressor use on digit survival after replantation and revascularization - a large retrospective cohort study.

Retrouvey H et al. · Microsurgery, 2019

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.